Immunomodulators
US10143746B2 · kind B2 · utility
8Cited by
4References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 1, 2017 |
| Grant date | Dec 4, 2018 |
| Priority date | — |
| Expiry date | Mar 7, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/55516
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.